FDA Approved: SINGULAIR — Supplemental Application (Organon LLC)

View source ↗

Summary

FDA approved a supplemental application for Singulair (montelukast sodium) from Organon LLC, resulting in a labeling change for the product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinitis
• Asthma
• Exercise-induced Bronchoconstriction

Drugs mentioned

• SINGULAIR (montelukast)

Snippet

SUPPL AP for SINGULAIR (MONTELUKAST SODIUM)